Please fill out the form below and we will gladly respond as soon as possible.
Synovial sarcoma most often develops near the large joints of the arms or legs, but in rare cases it can arise in the head and neck region. An especially uncommon presentation occurs in infants. A recently published case report describes synovial sarcoma originating in the parotid gland—the salivary gland located near the jaw and ear—in […]
UI Health Care has begun treating eligible patients with synovial sarcoma using a new form of immunotherapy known as T cell receptor (TCR) therapy. This treatment approach represents an important step forward in expanding access to innovative options for people facing advanced synovial sarcoma. A targeted immune-based approach TCR therapy is designed to help the […]
Researchers have studied prasterone—also known as DHEA (dehydroepiandrosterone)—as a potential treatment option for people with synovial sarcoma that has spread (metastatic) or cannot be removed through surgery. This clinical study was designed to better understand the safety of prasterone, determine appropriate dosing, and explore whether it could help slow or control disease progression. This trial […]
We are thrilled to announce a significant milestone for the Synovial Sarcoma Registry and Biospecimen Repository, as we proudly welcome our 100th registrant. This achievement signifies the growing commitment to advancing research and improving treatment options for patients with synovial sarcoma. The registry serves as a pivotal resource, collecting invaluable data and biospecimens from patients […]
Current Patient to Drive Relationships and Support for the Synovial Sarcoma Community [Philadelphia, PA] – 12/12/25 – The Synovial Sarcoma Foundation (SSF) is thrilled to announce the appointment of Julie Kramer as our new Community Engagement & Partnerships Manager. With a wealth of experience in advocacy and nonprofit communications, and as a survivor of synovial […]
The Synovial Sarcoma Foundation is dedicated to supporting cutting-edge research that advances treatment options for this rare and aggressive cancer. Recent findings published in The EMBO Journal highlight a promising new strategy: using drug blockers to target a problematic protein involved in synovial sarcoma’s genetics. Synovial sarcoma primarily develops in soft tissues such as muscles […]
The Synovial Sarcoma Foundation is committed to staying informed on the latest research and developments in this rare and aggressive cancer. A recent market report indicates that the global synovial sarcoma market is projected to grow significantly, reaching an estimated USD 420 million by 2034 — up from USD 245 million in 2024, at a […]